Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MANISH SHARMA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1790819332
CMS profile
1126262
Location
GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$659.76

21 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $659.76 21

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MANISH SHARMA

NPI 1790819332 · CMS profile ID 1126262

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

GRAND RAPIDS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–21 of 21 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1790819332?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

21 matching records · $659.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 21 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–21 of 21.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $14.4712/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673686549 CMS
Ipsen Biopharmaceuticals, Inc $17.0710/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640638413 CMS
AstraZeneca Pharmaceuticals LP $12.8610/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685625159 CMS
Foundation Medicine, Inc. $112.0810/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551585 CMS
Bayer HealthCare Pharmaceuticals Inc. $16.8908/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628469207 CMS
Foundation Medicine, Inc. $19.2508/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551583 CMS
Novo Nordisk Inc $13.3408/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704170771 CMS
TESARO, Inc. $13.9207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675569505 CMS
EMD Serono, Inc. $14.3306/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702993499 CMS
Taiho Oncology, Inc. $19.3906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679423277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $11.9306/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697397133 CMS
Foundation Medicine, Inc. $128.8005/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551581 CMS
Novartis Pharmaceuticals Corporation $20.2305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660098317 CMS
Celgene Corporation $14.3905/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672773265 CMS
Rigel Pharmaceuticals, Inc. $18.3404/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698994097 CMS
Ipsen Biopharmaceuticals, Inc $20.5503/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640622585 CMS
AstraZeneca Pharmaceuticals LP $13.0802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685223109 CMS
Amgen Inc. $21.5002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662682013 CMS
Ipsen Biopharmaceuticals, Inc $125.0402/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640640819 CMS
Lilly USA, LLC $13.9902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658005069 CMS
Foundation Medicine, Inc. $18.3102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551579 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $659.76 21
PY2020 $185.35 5
PY2021 $23.93 1
PY2022 $558.49 34
PY2023 $1,123.71 47
PY2024 $773.90 11
PY2025 $1,855.50 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $373.20 2
PY2025 Principal investigator $4,235,582.65 823
PY2024 Recipient $4,269.33 9
PY2024 Principal investigator $3,811,534.65 643
PY2023 Recipient $3,810.00 6
PY2023 Principal investigator $3,149,687.09 471
PY2022 Principal investigator $3,302,171.04 339
PY2021 Recipient $7,293.02 4
PY2021 Principal investigator $2,076,760.51 208
PY2020 Recipient $7,900.00 2
PY2020 Principal investigator $1,132,655.23 78
PY2019 Principal investigator $1,305,040.24 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

477 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $439.00 12/31/2023 Non-covered Recipient Entity
START MIDWEST
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with poor prognosis and limited treatment options. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors No dispute reported 06/30/2026 998415163
Principal investigator 1 AstraZeneca Pharmaceuticals LP $510.17 12/31/2023 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 991131711
Principal investigator 1 Merck Sharp & Dohme LLC $85,200.00 12/28/2023 Non-covered Recipient Entity
START Midwest
A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042566921
Principal investigator 1 PFIZER INC. $49,103.08 12/22/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046420167
Principal investigator 1 PFIZER INC. $9,105.76 12/22/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046440261
Principal investigator 1 GlaxoSmithKline, LLC. $2,970.00 12/21/2023 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1006132773
Principal investigator 1 Merck Sharp & Dohme LLC $170,400.00 12/15/2023 Non-covered Recipient Entity
South Texas Accelerated Research Therapeutics START Midwest
A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042567621
Principal investigator 1 PFIZER INC. $5,078.70 12/09/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046366233
Principal investigator 1 PFIZER INC. $3,368.25 12/08/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046417263
Principal investigator 1 PFIZER INC. $1,677.71 12/07/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046366083
Principal investigator 1 GlaxoSmithKline, LLC. $28,140.60 12/06/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132807
Principal investigator 1 ABBVIE INC. $364.50 12/04/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998410173
Principal investigator 1 ABBVIE INC. $2,813.27 12/04/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998410175
Principal investigator 1 MACROGENICS, INC. $1,173.79 12/04/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043830853
Principal investigator 1 MACROGENICS, INC. $1,671.76 12/04/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043830867
Principal investigator 1 MACROGENICS, INC. $711.39 12/04/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043830881
Principal investigator 1 Genmab U.S., Inc. $3,924.48 11/29/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392165
Principal investigator 1 PFIZER INC. $22,235.86 11/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046392727
Principal investigator 1 GlaxoSmithKline, LLC. $4,088.36 11/22/2023 Non-covered Recipient Entity
START MIDWEST
AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB No dispute reported 06/30/2026 1006132783
Principal investigator 1 Merck Sharp & Dohme LLC $234,300.00 11/21/2023 Non-covered Recipient Entity
START Midwest
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1042565935
Principal investigator 1 GlaxoSmithKline, LLC. $18,480.00 11/10/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132863
Principal investigator 1 PFIZER INC. $7,667.67 11/04/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046405207
Principal investigator 1 MACROGENICS, INC. $2,510.65 10/31/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043829543
Principal investigator 1 MACROGENICS, INC. $1,068.36 10/31/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043829557
Principal investigator 1 MACROGENICS, INC. $1,762.79 10/31/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043829569
Principal investigator 1 ABBVIE INC. $2,813.27 10/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998405437
Principal investigator 1 ABBVIE INC. $2,813.27 10/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998404959
Principal investigator 1 ABBVIE INC. $2,813.27 10/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998404961
Principal investigator 1 ABBVIE INC. $2,813.27 10/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998404963
Principal investigator 1 ABBVIE INC. $2,813.27 10/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998404991
Principal investigator 1 ABBVIE INC. $2,813.27 10/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998405121
Principal investigator 1 PFIZER INC. $7,443.23 10/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046397005
Principal investigator 1 PFIZER INC. $2,400.30 10/24/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046423733
Principal investigator 1 MACROGENICS, INC. $6,689.63 10/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043829225
Principal investigator 1 MACROGENICS, INC. $2,846.65 10/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043829237
Principal investigator 1 MACROGENICS, INC. $4,696.97 10/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043829251
Principal investigator 1 GlaxoSmithKline, LLC. $4,573.00 10/18/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132839
Principal investigator 1 PFIZER INC. $108.00 10/18/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046370943
Principal investigator 1 PFIZER INC. $650.00 10/16/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046377467
Principal investigator 1 PFIZER INC. $27,945.94 10/12/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046397247
Principal investigator 1 PFIZER INC. $71,437.67 10/12/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046427459
Principal investigator 1 ABBVIE INC. $2,813.27 10/02/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998401497
Principal investigator 1 ABBVIE INC. $2,813.27 10/02/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998401499
Principal investigator 1 ABBVIE INC. $2,813.27 10/02/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998401501
Principal investigator 1 ABBVIE INC. $2,813.27 10/02/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998401561
Principal investigator 1 PFIZER INC. $325.00 10/02/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046395797
Principal investigator 1 PFIZER INC. $32,356.51 09/22/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046387981
Principal investigator 1 PFIZER INC. $2,400.30 09/22/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046407141
Principal investigator 1 PFIZER INC. $14,104.97 09/05/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046376661
Principal investigator 1 PFIZER INC. $650.00 09/05/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046380011
Principal investigator 1 PFIZER INC. $63.00 09/05/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046380633
Principal investigator 1 PFIZER INC. $13,394.04 09/02/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046386803
Principal investigator 1 PFIZER INC. $16,279.40 09/02/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046408147
Principal investigator 1 PFIZER INC. $2,400.30 08/31/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046431021
Principal investigator 1 PFIZER INC. $1,300.00 08/28/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046374997
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396667
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396669
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396671
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396673
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396675
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396677
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396679
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396681
Principal investigator 1 ABBVIE INC. $1,208.25 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396683
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396685
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396687
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396689
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396703
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396705
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396707
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396709
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396711
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396713
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396715
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396717
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396719
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396721
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396727
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396729
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396731
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396733
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396735
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396737
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396739
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396741
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396743
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396745
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396747
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396749
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396751
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396753
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396755
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396763
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396765
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396767
Principal investigator 1 ABBVIE INC. $500.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396769
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396771
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396773
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396775
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396777
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396779
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396781
Principal investigator 1 ABBVIE INC. $2,713.37 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396783
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396785
Principal investigator 1 ABBVIE INC. $2,934.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396787
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396789
Principal investigator 1 ABBVIE INC. $364.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396791
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396793
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396813
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396815
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396817
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396819
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396821
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396823
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396825
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396827
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396829
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396831
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396833
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396835
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396837
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396839
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396841
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396843
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396859
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396861
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396863
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396865
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396867
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396869
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396871
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396873
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396875
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396877
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396879
Principal investigator 1 ABBVIE INC. $1,208.25 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396881
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396883
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396885
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396901
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396903
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396905
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396907
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396909
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396911
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396913
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396915
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396917
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396919
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396921
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396929
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396931
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396933
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396935
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396937
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396939
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396941
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396943
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396945
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396947
Principal investigator 1 ABBVIE INC. $3,002.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396957
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396959
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396961
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396963
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396965
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396967
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396969
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396971
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396973
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396975
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396977
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396989
Principal investigator 1 ABBVIE INC. $1,208.25 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396991
Principal investigator 1 ABBVIE INC. $1,208.25 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396993
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396995
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396997
Principal investigator 1 ABBVIE INC. $2,062.53 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396999
Principal investigator 1 ABBVIE INC. $1,034.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397001
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397003
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397005
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397009
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397021
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397023
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397025
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397027
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397029
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397031
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397037
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397039
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397041
Principal investigator 1 ABBVIE INC. $2,813.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397043
Principal investigator 1 ABBVIE INC. $2,537.87 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397045
Principal investigator 1 ABBVIE INC. $4,209.17 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397047
Principal investigator 1 ABBVIE INC. $2,941.52 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397049
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397051
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397053
Principal investigator 1 ABBVIE INC. $1,552.50 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397055
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397057
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397059
Principal investigator 1 ABBVIE INC. $1,196.10 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397061
Principal investigator 1 ABBVIE INC. $2,408.27 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397063
Principal investigator 1 ABBVIE INC. $1,968.03 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397065
Principal investigator 1 ABBVIE INC. $1,691.28 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397067
Principal investigator 1 ABBVIE INC. $2,718.77 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397069
Principal investigator 1 ABBVIE INC. $1,113.75 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397071
Principal investigator 1 ABBVIE INC. $1,472.85 08/25/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998397073
Principal investigator 1 PFIZER INC. $34,910.04 08/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046421487
Principal investigator 1 ABBVIE INC. $125.35 08/21/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396245
Principal investigator 1 ABBVIE INC. $125.35 08/21/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396247
Principal investigator 1 ABBVIE INC. $125.35 08/21/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396253
Principal investigator 1 ABBVIE INC. $125.35 08/21/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396261
Principal investigator 1 ABBVIE INC. $125.35 08/21/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998396265
Principal investigator 1 PFIZER INC. $16,837.92 08/14/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046374983
Principal investigator 1 PFIZER INC. $17,508.68 08/14/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046376921
Principal investigator 1 PFIZER INC. $325.00 08/14/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046377523
Principal investigator 1 PFIZER INC. $5,460.41 08/11/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046422303
Principal investigator 1 ABBVIE INC. $4,749.17 08/07/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998393415
Principal investigator 1 PFIZER INC. $4,609.58 08/05/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046417223
Principal investigator 1 GlaxoSmithKline, LLC. $7,572.00 08/04/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132827
Principal investigator 1 MACROGENICS, INC. $7,644.97 08/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043827185
Principal investigator 1 MACROGENICS, INC. $3,253.18 08/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043827197
Principal investigator 1 MACROGENICS, INC. $5,367.75 08/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043827211
Principal investigator 1 PFIZER INC. $325.00 08/01/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046375803
Principal investigator 1 PFIZER INC. $72,318.61 07/26/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046408529
Principal investigator 1 PFIZER INC. $20,903.43 07/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046410337
Principal investigator 1 PFIZER INC. $15,438.61 07/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046485361
Principal investigator 1 PFIZER INC. $108.00 07/24/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046377659
Principal investigator 1 PFIZER INC. $14,104.97 07/24/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046380651
Principal investigator 1 PFIZER INC. $325.00 07/19/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046376501
Principal investigator 1 PFIZER INC. $19,134.00 07/17/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046367677
Principal investigator 1 PFIZER INC. $35,017.36 07/17/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046376557
Principal investigator 1 Genmab U.S., Inc. $4,981.50 07/13/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392159
Principal investigator 1 PFIZER INC. $36.00 07/12/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046376487
Principal investigator 1 PFIZER INC. $650.00 07/12/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046376543
Principal investigator 1 PFIZER INC. $14,104.97 07/11/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046377551
Principal investigator 1 PFIZER INC. $325.00 07/11/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046380025
Principal investigator 1 PFIZER INC. $54.00 07/11/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046380829
Principal investigator 1 PFIZER INC. $40,497.01 07/11/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046409183
Principal investigator 1 PFIZER INC. $1,300.00 07/10/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046377537
Principal investigator 1 PFIZER INC. $29,862.35 07/08/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046498212
Principal investigator 1 MACROGENICS, INC. $5,483.15 07/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043824319
Principal investigator 1 MACROGENICS, INC. $2,333.26 07/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043824333
Principal investigator 1 MACROGENICS, INC. $3,849.87 07/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043824347
Principal investigator 1 Genmab U.S., Inc. $654.08 06/28/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392053
Principal investigator 1 Genmab U.S., Inc. $337.50 06/28/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392109
Principal investigator 1 PFIZER INC. $1,625.00 06/21/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046468625
Principal investigator 1 GlaxoSmithKline, LLC. $4,092.00 06/14/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132795
Principal investigator 1 PFIZER INC. $35,017.36 06/13/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492265
Principal investigator 1 PFIZER INC. $15,307.20 06/13/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046495071
Principal investigator 1 ABBVIE INC. $60.75 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386563
Principal investigator 1 ABBVIE INC. $94.50 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386565
Principal investigator 1 ABBVIE INC. $25.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386567
Principal investigator 1 ABBVIE INC. $438.75 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386569
Principal investigator 1 ABBVIE INC. $270.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386571
Principal investigator 1 ABBVIE INC. $60.75 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386573
Principal investigator 1 ABBVIE INC. $14.12 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386575
Principal investigator 1 ABBVIE INC. $20.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386577
Principal investigator 1 ABBVIE INC. $250.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386579
Principal investigator 1 ABBVIE INC. $500.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386581
Principal investigator 1 ABBVIE INC. $250.00 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386587
Principal investigator 1 ABBVIE INC. $438.75 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386589
Principal investigator 1 ABBVIE INC. $79.65 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386591
Principal investigator 1 ABBVIE INC. $17.51 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386593
Principal investigator 1 ABBVIE INC. $128.25 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386595
Principal investigator 1 ABBVIE INC. $67.50 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998386597
Principal investigator 1 MACROGENICS, INC. $7,256.18 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043823967
Principal investigator 1 MACROGENICS, INC. $3,087.74 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043823979
Principal investigator 1 MACROGENICS, INC. $5,094.77 06/09/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043823995
Principal investigator 1 PFIZER INC. $81.00 06/07/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492457
Principal investigator 1 PFIZER INC. $24,536.00 06/07/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1046495045
Principal investigator 1 PFIZER INC. $1,625.00 06/05/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046466277
Principal investigator 1 PFIZER INC. $9,001.81 06/03/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046531879
Principal investigator 1 PFIZER INC. $24,430.98 06/03/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046532505
Principal investigator 1 PFIZER INC. $2,722.95 06/02/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046513025
Recipient PFIZER INC. $940.00 06/02/2023 Covered Recipient Physician PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1061083249
Recipient PFIZER INC. $940.00 06/02/2023 Covered Recipient Physician PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1061083499
Recipient PFIZER INC. $940.00 06/02/2023 Covered Recipient Physician PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1061083501
Principal investigator 1 Genmab U.S., Inc. $1,000.00 05/25/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392059
Principal investigator 1 PFIZER INC. $20,472.00 05/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046374289
Principal investigator 1 PFIZER INC. $3,170.48 05/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046439455
Principal investigator 1 PFIZER INC. $15,269.55 05/25/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046523979
Principal investigator 1 ABBVIE INC. $2,934.77 05/22/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998384105
Principal investigator 1 PFIZER INC. $650.00 05/16/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046463857
Principal investigator 1 PFIZER INC. $18.00 05/16/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492245
Principal investigator 1 PFIZER INC. $17,508.68 05/15/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046466297
Principal investigator 1 PFIZER INC. $19,134.00 05/15/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046490747
Principal investigator 1 Genmab U.S., Inc. $200.00 05/11/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392041
Principal investigator 1 Genmab U.S., Inc. $405.00 05/11/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392079
Principal investigator 1 MACROGENICS, INC. $1,212.60 05/10/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043816757
Principal investigator 1 MACROGENICS, INC. $516.00 05/10/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043816771
Principal investigator 1 MACROGENICS, INC. $851.40 05/10/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043816785
Principal investigator 1 MACROGENICS, INC. $1,598.56 05/10/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043816797
Principal investigator 1 MACROGENICS, INC. $680.24 05/10/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043816811
Principal investigator 1 MACROGENICS, INC. $1,122.40 05/10/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043816823
Principal investigator 1 PFIZER INC. $124,151.83 05/10/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046434597
Principal investigator 1 PFIZER INC. $18,095.86 05/06/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046521247
Principal investigator 1 PFIZER INC. $14,062.62 05/06/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046525451
Principal investigator 1 Exelixis Inc. $1,310.00 05/05/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947197
Principal investigator 1 Exelixis Inc. $1,020.00 05/05/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947203
Principal investigator 1 Exelixis Inc. $1,352.00 05/05/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947211
Principal investigator 1 Genmab U.S., Inc. $2,204.55 05/04/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038391999
Principal investigator 1 Genmab U.S., Inc. $150.00 05/04/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392153
Principal investigator 1 ABBVIE INC. $2,516.27 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380267
Principal investigator 1 ABBVIE INC. $2,435.27 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380269
Principal investigator 1 ABBVIE INC. $3,337.08 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380275
Principal investigator 1 ABBVIE INC. $2,610.77 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380287
Principal investigator 1 ABBVIE INC. $1,499.85 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380289
Principal investigator 1 ABBVIE INC. $3,812.27 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380295
Principal investigator 1 ABBVIE INC. $2,366.28 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380311
Principal investigator 1 ABBVIE INC. $2,934.77 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380313
Principal investigator 1 ABBVIE INC. $2,934.77 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380315
Principal investigator 1 ABBVIE INC. $2,366.28 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380317
Principal investigator 1 ABBVIE INC. $1,499.85 05/03/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998380319
Principal investigator 1 ABBVIE INC. $364.50 05/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379965
Principal investigator 1 ABBVIE INC. $2,934.77 05/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379967
Principal investigator 1 ABBVIE INC. $2,934.77 05/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379969
Principal investigator 1 ABBVIE INC. $500.85 05/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379971
Principal investigator 1 ABBVIE INC. $2,713.37 05/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379975
Principal investigator 1 ABBVIE INC. $50.00 04/26/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998379523
Principal investigator 1 Genmab U.S., Inc. $337.50 04/26/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392097
Principal investigator 1 MACROGENICS, INC. $4,673.00 04/26/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043816493
Principal investigator 1 PFIZER INC. $18,351.10 04/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046440351
Principal investigator 1 PFIZER INC. $2,380.00 04/22/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046435537
Principal investigator 1 PFIZER INC. $14,942.59 04/22/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046477149
Principal investigator 1 Genmab U.S., Inc. $274.73 04/20/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392011
Principal investigator 1 Genmab U.S., Inc. $274.73 04/20/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392128
Principal investigator 1 Eli Lilly and Company $8,075.00 04/18/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC
A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES No dispute reported 06/30/2026 1038137361
Principal investigator 1 PFIZER INC. $10,509.77 04/14/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046477853
Principal investigator 1 Genmab U.S., Inc. $150.00 04/13/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392023
Principal investigator 1 Genmab U.S., Inc. $2,313.90 04/13/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392147
Principal investigator 1 PFIZER INC. $45.00 04/13/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046490771
Principal investigator 1 PFIZER INC. $28,209.94 04/13/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492415
Principal investigator 1 Exelixis Inc. $10,810.00 04/12/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947219
Principal investigator 1 MACROGENICS, INC. $618.64 04/12/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043798159
Principal investigator 1 MACROGENICS, INC. $263.25 04/12/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043798169
Principal investigator 1 MACROGENICS, INC. $434.36 04/12/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043798179
Principal investigator 1 PFIZER INC. $21,971.20 04/12/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046438531
Principal investigator 1 PFIZER INC. $33,800.13 04/12/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046438559
Principal investigator 1 PFIZER INC. $18,417.89 04/12/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046475675
Principal investigator 1 PFIZER INC. $1,950.00 04/12/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492435
Principal investigator 1 PFIZER INC. $1,625.00 04/10/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046464185
Principal investigator 1 PFIZER INC. $650.00 04/10/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046492569
Principal investigator 1 PFIZER INC. $2,050.70 04/07/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046476935
Principal investigator 1 ABBVIE INC. $2,340.00 04/05/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998376997
Principal investigator 1 Exelixis Inc. $203.00 03/31/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947127
Principal investigator 1 MACROGENICS, INC. $1,828.82 03/30/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043797839
Principal investigator 1 PFIZER INC. $19,134.00 03/29/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046466853
Principal investigator 1 PFIZER INC. $35,017.36 03/29/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046467023
Principal investigator 1 PFIZER INC. $650.00 03/27/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046468557
Principal investigator 1 PFIZER INC. $199,588.63 03/25/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046451868
Principal investigator 1 PFIZER INC. $14,552.68 03/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046448873
Principal investigator 1 PFIZER INC. $25,682.07 03/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046456741
Principal investigator 1 PFIZER INC. $10,647.10 03/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046546739
Principal investigator 1 PFIZER INC. $27.00 03/22/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046466509
Principal investigator 1 Exelixis Inc. $1,054.00 03/20/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947143
Principal investigator 1 Exelixis Inc. $720.00 03/20/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947175
Principal investigator 1 MACROGENICS, INC. $6,435.24 03/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797551
Principal investigator 1 MACROGENICS, INC. $2,738.40 03/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797559
Principal investigator 1 MACROGENICS, INC. $4,518.36 03/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797571
Principal investigator 1 Genmab U.S., Inc. $3,157.65 03/16/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392115
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373789
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373795
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373797
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373805
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373807
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373809
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373819
Principal investigator 1 ABBVIE INC. $100.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373821
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373823
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373825
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373831
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373833
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373841
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373843
Principal investigator 1 ABBVIE INC. $50.00 03/15/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998373845
Principal investigator 1 PFIZER INC. $1,625.00 03/13/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046494003
Principal investigator 1 Genmab U.S., Inc. $654.08 03/09/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392085
Principal investigator 1 ABBVIE INC. $36.18 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372691
Principal investigator 1 ABBVIE INC. $36.18 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372699
Principal investigator 1 ABBVIE INC. $27.41 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372713
Principal investigator 1 ABBVIE INC. $1,925.00 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372719
Principal investigator 1 ABBVIE INC. $2,920.00 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372731
Principal investigator 1 ABBVIE INC. $27.41 03/08/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998372733
Principal investigator 1 PFIZER INC. $9,061.88 03/07/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046448213
Principal investigator 1 PFIZER INC. $21,046.00 03/07/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046458233
Principal investigator 1 PFIZER INC. $18,019.65 03/04/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046446775
Principal investigator 1 PFIZER INC. $2,200.00 03/04/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS No dispute reported 06/30/2026 1046447093
Principal investigator 1 PFIZER INC. $1,350.00 03/04/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046544599
Principal investigator 1 Genmab U.S., Inc. $350.00 03/03/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392071
Principal investigator 1 Genmab U.S., Inc. $405.00 03/03/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392091
Principal investigator 1 ABBVIE INC. $450.00 03/01/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371999
Principal investigator 1 PFIZER INC. $17,985.50 02/25/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046368397
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371823
Principal investigator 1 ABBVIE INC. $100.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371825
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371827
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371829
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371831
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371833
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371835
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371837
Principal investigator 1 ABBVIE INC. $100.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371839
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371841
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371843
Principal investigator 1 ABBVIE INC. $50.00 02/24/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998371889
Principal investigator 1 Exelixis Inc. $2,751.00 02/24/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947093
Principal investigator 1 PFIZER INC. $18,152.78 02/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046453551
Principal investigator 1 PFIZER INC. $33,003.34 02/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046459943
Principal investigator 1 Genmab U.S., Inc. $4,071.60 02/23/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392005
Principal investigator 1 MACROGENICS, INC. $5,558.15 02/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797113
Principal investigator 1 MACROGENICS, INC. $2,365.17 02/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797125
Principal investigator 1 MACROGENICS, INC. $3,902.53 02/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043797135
Principal investigator 1 PFIZER INC. $17,508.68 02/22/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046466213
Principal investigator 1 PFIZER INC. $19,134.00 02/22/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046490057
Principal investigator 1 PFIZER INC. $27.00 02/20/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046466463
Principal investigator 1 PFIZER INC. $14,104.97 02/20/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046498409
Principal investigator 1 Genmab U.S., Inc. $202.50 02/16/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392029
Principal investigator 1 Genmab U.S., Inc. $250.00 02/16/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392035
Principal investigator 1 Genmab U.S., Inc. $4,981.50 02/16/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392135
Principal investigator 1 Exelixis Inc. $714.00 02/15/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947079
Principal investigator 1 Exelixis Inc. $655.00 02/15/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947109
Principal investigator 1 Exelixis Inc. $405.00 02/15/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947183
Principal investigator 1 MACROGENICS, INC. $78.00 02/14/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043793013
Recipient PFIZER INC. $330.00 02/13/2023 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046527817
Recipient PFIZER INC. $330.00 02/13/2023 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046527837
Recipient PFIZER INC. $330.00 02/13/2023 Covered Recipient Physician ELRANATAMAB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046531195
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $121,583.00 02/10/2023 Non-covered Recipient Entity
Start Midwest
PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer No dispute reported 06/30/2026 1027454885
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,053.66 02/08/2023 Non-covered Recipient Entity
CANCER AND HEMATOLOGY
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 991133783
Principal investigator 1 Exelixis Inc. $2,751.00 02/08/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947119
Principal investigator 1 Exelixis Inc. $5,270.65 02/08/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947135
Principal investigator 1 ABBVIE INC. $67.50 02/06/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998368787
Principal investigator 1 ABBVIE INC. $114.75 02/06/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998368789
Principal investigator 1 PFIZER INC. $3,631.85 02/04/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046496449
Principal investigator 1 PFIZER INC. $3,030.41 02/03/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046457845
Principal investigator 1 PFIZER INC. $4,372.05 02/03/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1046462435
Principal investigator 1 PFIZER INC. $33,682.35 02/03/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046462593
Principal investigator 1 ABBVIE INC. $1,930.16 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367749
Principal investigator 1 ABBVIE INC. $4,291.31 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367751
Principal investigator 1 ABBVIE INC. $5,000.00 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367753
Principal investigator 1 ABBVIE INC. $2,267.66 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367755
Principal investigator 1 ABBVIE INC. $500.85 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367757
Principal investigator 1 ABBVIE INC. $1,036.00 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367759
Principal investigator 1 ABBVIE INC. $2,551.16 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367761
Principal investigator 1 ABBVIE INC. $2,362.16 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367763
Principal investigator 1 ABBVIE INC. $364.50 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367767
Principal investigator 1 ABBVIE INC. $1,979.10 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367769
Principal investigator 1 ABBVIE INC. $3,589.31 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367771
Principal investigator 1 ABBVIE INC. $2,462.06 01/30/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367773
Principal investigator 1 PFIZER INC. $1,950.00 01/30/2023 Non-covered Recipient Entity
START Midwest
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046485423
Principal investigator 1 Exelixis Inc. $675.00 01/27/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947101
Principal investigator 1 Exelixis Inc. $2,751.30 01/27/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947151
Principal investigator 1 Exelixis Inc. $74.25 01/27/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947159
Principal investigator 1 Genmab U.S., Inc. $1,000.00 01/26/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392065
Principal investigator 1 Genmab U.S., Inc. $1,925.00 01/26/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392121
Principal investigator 1 Genmab U.S., Inc. $274.73 01/26/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392139
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 01/25/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132817
Principal investigator 1 GlaxoSmithKline, LLC. $600.00 01/25/2023 Non-covered Recipient Entity
MULTIPLE DOCTORS
AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD No dispute reported 06/30/2026 1006132849
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,481.28 01/24/2023 Non-covered Recipient Entity
Start Midwest
Phase I/II TIM3 FIH Monotherapy/Nivo Combination in advanced solid tumors No dispute reported 06/30/2026 1027454873
Principal investigator 1 PFIZER INC. $35,017.36 01/24/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046495939
Principal investigator 1 PFIZER INC. $15,307.20 01/24/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046498425
Principal investigator 1 PFIZER INC. $2,888.33 01/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046537723
Principal investigator 1 PFIZER INC. $723.60 01/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046537929
Principal investigator 1 PFIZER INC. $16,709.64 01/24/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046544207
Principal investigator 1 ABBVIE INC. $2,340.00 01/23/2023 Non-covered Recipient Entity
START MIDWEST LLC
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 No dispute reported 06/30/2026 998367145
Principal investigator 1 Exelixis Inc. $663.00 01/23/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947167
Principal investigator 1 PFIZER INC. $3,846.15 01/21/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046542093
Principal investigator 1 MACROGENICS, INC. $104.00 01/17/2023 Non-covered Recipient Entity
SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST
MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER No dispute reported 06/30/2026 1043792517
Principal investigator 1 MACROGENICS, INC. $17,133.40 01/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043792527
Principal investigator 1 MACROGENICS, INC. $7,290.81 01/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043792537
Principal investigator 1 MACROGENICS, INC. $12,029.84 01/17/2023 Non-covered Recipient Entity
START MIDWEST LLC
A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES No dispute reported 06/30/2026 1043792547
Principal investigator 1 PFIZER INC. $18.00 01/16/2023 Non-covered Recipient Entity
START Midwest
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046487833
Principal investigator 1 Exelixis Inc. $74.25 01/13/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947085
Principal investigator 1 Exelixis Inc. $81.00 01/13/2023 Non-covered Recipient Entity
START MidWest LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1041947191
Principal investigator 1 Genmab U.S., Inc. $405.00 01/12/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392017
Principal investigator 1 Genmab U.S., Inc. $4,071.60 01/12/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392047
Principal investigator 1 Genmab U.S., Inc. $250.00 01/12/2023 Non-covered Recipient Entity
THE START CENTER FOR CANCER CARE
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. No dispute reported 06/30/2026 1038392103
Principal investigator 1 PFIZER INC. $1,300.00 01/10/2023 Non-covered Recipient Entity
START Midwest
A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046468537
Principal investigator 1 PFIZER INC. $42,734.25 01/07/2023 Non-covered Recipient Entity
START Midwest LLC
A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1046538881
Principal investigator 1 PFIZER INC. $167.00 01/06/2023 Non-covered Recipient Entity
START Midwest LLC
PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY No dispute reported 06/30/2026 1046545609